<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NOVOLIN
                                     R- insulin human injection, solution </strong><br>TYA Pharmaceuticals<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Novolin R safely and effectively.  See full prescribing information for Novolin R. Initial U.S. Approval: 1991
        <br><br><span class="Bold">Novolin R (Regular, Human Insulin [rDNA origin] USP) solution for subcutaneous or intravenous use
            <span class="Sup">®</span></span><br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Warnings and Precautions ( )	                          3/2013
                                    <a href="#ID_d62c2dda-a447-4641-8e48-76fe3b5f67d9">5.9</a> </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Novolin R is a short-acting recombinant human insulin indicated to improve glycemic control in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus ( ).
                                    <a href="#ID_40ba9004-8e31-4ad7-9a59-f5f07d49ad24">1</a> </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>The dosage and timing of Novolin R must be individualized ( ).
                                        <a href="#ID_977d6f9c-b757-4474-91f9-9895ceb9c259">2.1</a>
</dd>
<dt>•</dt>
<dd>Subcutaneous injection: Administer approximately 30 minutes prior to the start of a meal ( ).
                                        <a href="#ID_e5e27c30-eccf-42de-b997-3f120dbda04d">2.2</a>
</dd>
<dt>•</dt>
<dd>Intravenous use: Use at concentrations from 0.05 to 1.0 Unit/mL in infusion systems using polypropylene infusion bags. Novolin R is stable in 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/L potassium chloride ( ).
                                        <a href="#ID_87ef8374-86e9-47f2-918f-f404b3bde6bc">2.3</a>
</dd>
<dt>•</dt>
<dd>Use in pumps: Not recommended due to risk of precipitation ( ).
                                        <a href="#ID_71ea3c55-6a95-4e1a-b93f-7877da778c57">2.4</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Novolin R, Regular, Human Insulin Injection (rDNA origin) USP, 100 units/mL (U-100), is supplied in 10 mL vials ( ).
                                    <a href="#ID_681263ad-cb7c-419f-b175-2aad1913d2d8">3</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Do not use during episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> ( ).
                                        <a href="#ID_05f08df6-3ce5-4751-b41f-7865a318b37e">4</a>
</dd>
<dt>•</dt>
<dd>Do not use in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Novolin R or one of its excipients ( ).
                                        <a href="#ID_05f08df6-3ce5-4751-b41f-7865a318b37e">4</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: Most common adverse reaction of insulin therapy and may be life-threatening. Closely monitor blood glucose. Changes in insulin or dosage should be made cautiously and only under medical supervision ( ).
                                        <a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>: Particularly when insulin is given intravenously or in settings of poor glycemic control.  Use caution in patients predisposed to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> ( ).
                                        <a href="#ID_b6491964-d031-43f0-99f6-404cf4dcebf4">5.3</a>
</dd>
<dt>•</dt>
<dd>Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>: As with other insulins, the dose requirements for Novolin R may be reduced ( ).
                                        <a href="#ID_b0fa5b5b-1d1c-4468-a9ce-277ccb789bef">5.5</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>: Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, may occur ( ).
                                        <a href="#ID_6c81cdc9-32b0-40ff-a400-dbcf385fe918">5.6</a>
</dd>
<dt>•</dt>
<dd>Mixing: Do not mix Novolin R with any insulin for intravenous use. Do not mix with insulins other than NPH insulin for subcutaneous use ( ).
                                        <a href="#ID_2a564b13-ca96-4f15-a918-fb42ab87f568">5.7</a>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including Novolin R ( ).
                                        <a href="#ID_d62c2dda-a447-4641-8e48-76fe3b5f67d9">5.9</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Italics">Adverse reactions observed with Novolin R include <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> ( ).
                                        <a href="#ID_8268e458-6c36-4917-a598-1320337d7343">6</a></span> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact</span><span class="Bold">Novo Nordisk Inc. at 1-800-727-6500</span><span class="Bold">or FDA at 1-800-FDA-1088 or</span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Certain medications affect glucose metabolism and may require insulin dose adjustment and close monitoring ( ).
                                        <a href="#ID_0b3bd463-7493-4e9c-af40-509b2bb0a140">7</a>
</dd>
<dt>•</dt>
<dd>The signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent in patients taking anti-adrenergic medications (e.g., beta-blockers, clonidine, guanethidine, and reserpine) ( ).
                                        <a href="#ID_0b3bd463-7493-4e9c-af40-509b2bb0a140">7</a>
</dd>
</dl></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 10/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Treatment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Subcutaneous Injection</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Intravenous Use</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Use in Insulin Pumps</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Administration</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span>, and Hyperosmolar Hyperglycemic Non-Ketotic  Syndrome</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Mixing of Insulins</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Antibody Production</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with concomitant use of PPAR-gamma agonists</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (adults)</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (adults)</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (children and adolescents)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Recommended Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Instructions for All Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_32b6b60d-55b2-4fa5-9043-c02456ce6f7a"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_511af18a-03e0-443c-8ee2-a48803a46b98"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Treatment of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Novolin R is indicated to improve glycemic control in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_76ca7fe3-6f9c-4bab-904c-515e19551d23"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_977d6f9c-b757-4474-91f9-9895ceb9c259"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing</h2>
<p class="First">The dosage and timing of Novolin R must be individualized. Blood glucose monitoring is essential for all patients receiving insulin therapy.</p>
<p>Total daily insulin requirements vary and are usually between 0.5 and 1.0 units/kg/day.  Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e5e27c30-eccf-42de-b997-3f120dbda04d"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Subcutaneous Injection</h2>
<p class="First">Novolin R should generally be injected approximately 30 minutes prior to the start of a meal.</p>
<p>Novolin R given by subcutaneous injection should generally be used in regimens that include an intermediate or long-acting insulin .
                                    <span class="Italics">[see How Supplied/Storage and Handling ( , )]
                                        <a href="#ID_bef8e3b2-3193-4739-a06e-d9c7314e988b">16.1</a><a href="#ID_55c67219-4d5b-4200-b9c2-af8fc1b4235f">16.2</a></span></p>
<p>Novolin R should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or the upper arm.  Subcutaneous injection into the abdominal wall is generally associated with faster absorption than other injection sites.  Injection sites should be rotated within the same region to reduce the risk of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.  Injection into a lifted skin fold minimizes the risk of intramuscular injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_87ef8374-86e9-47f2-918f-f404b3bde6bc"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Intravenous Use</h2>
<p class="First">Novolin R can be administered intravenously under medical supervision for glycemic control, with close monitoring of blood glucose and potassium concentrations to avoid <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> .
                                    <span class="Italics">[see Warnings and Precautions ( , ), How Supplied/Storage and Handling ( , )]
                                        <a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a><a href="#ID_b6491964-d031-43f0-99f6-404cf4dcebf4">5.3</a><a href="#ID_bef8e3b2-3193-4739-a06e-d9c7314e988b">16.1</a><a href="#ID_55c67219-4d5b-4200-b9c2-af8fc1b4235f">16.2</a></span></p>
<p>Intravenous administration of insulin is commonly used in the treatment of <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, peri-operative management of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, and maintenance of glycemic control during labor in pregnant diabetic women. For intravenous use, Novolin R should be used at concentrations from 0.05 units/mL to 1.0 unit/mL in infusion systems using polypropylene infusion bags.  Novolin R can be used with the following infusion fluids: 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/L potassium chloride.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Never use Novolin R if it has become viscous or cloudy; use Novolin R only if it is clear and colorless.  Vials should not be used if leakage is observed.  Novolin R should not be used after the printed expiration date.</p>
<p>The onset of action of Novolin R, when administered intravenously, is more rapid in comparison to subcutaneous administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_71ea3c55-6a95-4e1a-b93f-7877da778c57"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Use in Insulin Pumps</h2>
<p class="First">Use of Novolin R in insulin pumps is not recommended because of the risk of precipitation.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_681263ad-cb7c-419f-b175-2aad1913d2d8"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>•</dt>
<dd>Novolin R is available in 10 mL vials. The concentration of Novolin R is 100 USP units of human insulin (rDNA origin)/mL.
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_05f08df6-3ce5-4751-b41f-7865a318b37e"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Novolin R is contraindicated:</p>
<dl>
<dt>•</dt>
<dd>During episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>
                                </dd>
<dt>•</dt>
<dd>In patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Novolin R or one of its excipients
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_99ba38fa-bdb7-40c6-af5e-d25fd9eb8ec0"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_321a0bcf-bb5c-4dd7-94d2-affeb0f4017d"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Administration</h2>
<p class="First">Subcutaneous injection of Novolin R should be followed by a meal. Patients should wait approximately 30 minutes after injection before starting the meal [ ].
                                    <span class="Italics">see Dosage and Administration ( )
                                        <a href="#ID_e5e27c30-eccf-42de-b997-3f120dbda04d">2.2</a></span></p>
<p>Any change of insulin dose should be made cautiously and only under medical supervision.  Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of Novolin R action may vary in different individuals or at different times in the same individual and is dependent on many conditions, including dosage, the site of injection, local blood supply, temperature, and physical activity. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosages.  Insulin requirements may be altered during illness, <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span>, or other stresses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most common adverse reaction of all insulin therapies, including Novolin R.  Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may lead to <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, temporary or permanent impairment of brain function or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> requiring the assistance of another person, parenteral glucose infusion, and glucagon administration has been observed in clinical trials with insulin, including trials with Novolin R.</p>
<p>The timing of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually reflects the time-action profile of the administered insulin formulations [ ].  Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> [ ]. As with all insulins, use caution in patients with <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> unawareness and in patients who may be predisposed to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (e.g., patients who are fasting or have erratic food intake, pediatric patients, and the elderly).  The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.
                                    <span class="Italics">see Clinical Pharmacology ( , )
                                        <a href="#ID_65c16400-e3cd-4ffc-abc9-661a3369f281">12.2</a><a href="#ID_3ada60b6-c21f-4060-a4ad-4418770e4505">12.3</a></span><span class="Italics">see Drug Interactions ( )
                                        <a href="#ID_0b3bd463-7493-4e9c-af40-509b2bb0a140">7</a></span></p>
<p>Rapid changes in serum glucose concentrations may induce symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, regardless of the glucose value.  Early warning symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be different or less pronounced under certain conditions, such as longstanding <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="4044391" conceptname="Diabetic neuropathy">diabetic neuropathy</span>, use of medications such as beta-blockers, or intensified glycemic control [ ]. These situations may result in severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (and, possibly, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>) prior to the patient’s awareness of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.  Intravenously administered insulin has a more rapid onset of action than subcutaneously administered insulin, requiring more close monitoring for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                    <span class="Italics">see Drug Interactions ( )
                                        <a href="#ID_0b3bd463-7493-4e9c-af40-509b2bb0a140">7</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b6491964-d031-43f0-99f6-404cf4dcebf4"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></h2>
<p class="First">All insulins, including Novolin R, cause a shift in potassium from the extracellular to intracellular space, possibly leading to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> that, if left untreated, may cause <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Use caution in patients who may be at risk for <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> (e.g., patients using potassium-lowering medications and patients taking medications sensitive to serum potassium concentrations). Monitor glucose and potassium frequently when Novolin R is administered intravenously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_009a8ab0-7123-4615-9e7f-f7851fceb728"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic Ketoacidosis</span>, and Hyperosmolar Hyperglycemic Non-Ketotic  Syndrome</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, or hyperosmolar hyperglycemic non-ketotic syndrome may develop in patients who take less insulin than needed to control blood glucose.  These conditions can be precipitated by illness, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, dietary indiscretion, or omission or improper administration of the prescribed insulin dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_b0fa5b5b-1d1c-4468-a9ce-277ccb789bef"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">As with other insulins, the dose requirements for Novolin R may be reduced in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6c81cdc9-32b0-40ff-a400-dbcf385fe918"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">- As with other insulins, patients may experience <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> at the site of injection of Novolin R.  These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation of Novolin R.  In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.  Localized reactions and generalized <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgias</span> have been reported with the use of meta-cresol, which is an excipient in Novolin R.
                                    <span class="Italics">Local Reactions</span></p>
<p>- Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur with any insulin, including Novolin R.  Generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to insulin may manifest as a whole body <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (including <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, or <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>.
                                    <span class="Italics">Systemic Reactions</span><span class="Italics">,</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_2a564b13-ca96-4f15-a918-fb42ab87f568"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Mixing of Insulins</h2>
<p class="First">If Novolin R is mixed with NPH human insulin, Novolin R should be drawn into the syringe first and the mixture should be injected immediately after mixing. Insulin mixtures should not be administered intravenously.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bed37a03-2a94-4d4b-ac50-08accb0118ad"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Antibody Production</h2>
<p class="First">Increases in titers of anti-insulin antibodies that react with human insulin have been observed in patients treated with Novolin R. Data from a 12-month controlled trial in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> suggest that the increase in these antibodies is transient.  The clinical significance of these antibodies is not known but does not appear to cause deterioration in glycemic control or necessitate increases in insulin dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d62c2dda-a447-4641-8e48-76fe3b5f67d9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with concomitant use of PPAR-gamma agonists</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, particularly when used in combination with insulin. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Patients treated with insulin, including NOVOLIN R, and a PPAR-gamma agonist should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_8268e458-6c36-4917-a598-1320337d7343"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></span></dd>
</dl>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most commonly observed adverse reaction in patients using insulin, including Novolin R [ ].
                            <span class="Italics">see Warnings and Precautions ( )
                                <a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a></span></p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline">Insulin initiation and glucose control intensification</span></span></dd>
</dl>
<p>Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic <span class="product-label-link" type="condition" conceptid="380727" conceptname="Transient refractive change">refraction disorder</span>, worsening of <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, and acute painful <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>. Over the long-term, improved glycemic control decreases the risk of <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span></span></span></dd>
</dl>
<p>Long-term use of insulin, including Novolin R, can cause <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> at the site of repeated insulin injections. <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> includes <span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span> (thickening of adipose tissue) and <span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span> (thinning of adipose tissue), and may affect insulin absorption. Rotate insulin injection sites within the same region to reduce the risk of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span></span></span></dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> can occur with insulin therapies, including Novolin R, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.</p>
<dl>
<dt>•</dt>
<dd><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></span></span></dd>
</dl>
<p>Insulin may cause <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, particularly if previously poor metabolic control is improved by intensified insulin therapy. These symptoms are usually transitory.</p>
<dl>
<dt>•</dt>
<dd><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span></span></dd>
</dl>
<p>As with other insulins, Novolin R can cause <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>. Severe, life-threatening, generalized <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> may occur with any insulin, including Novolin R [ ].
                            <span class="Italics">see Warnings and Precautions ( )
                                <a href="#ID_6c81cdc9-32b0-40ff-a400-dbcf385fe918">5.6</a></span></p>
<p><span class="Bold"><span class="Italics">Clinical Trial Experience</span></span></p>
<p>Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared to those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.</p>
<p><span class="Italics">Adults with type 1 or type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></span></p>
<p>The incidence of adverse reactions during clinical trials comparing Novolin R and insulin aspart in adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus are listed in the tables below.</p>
<p><span class="Bold">Table 1: Adverse Reactions in a 24-Week Trial Comparing Novolin R and Insulin Aspart in Adults with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Also Treated with NPH Insulin (adverse reactions with an incidence ≥ 5% in the Novolin R treatment group are listed)</span></p>
<table>
<col width="37%">
<col width="19%">
<col width="23%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Novolin R + NPH</span><br><span class="Bold">N= 286</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Insulin aspart + NPH</span><br><span class="Bold">N=596</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was defined as an episode of blood glucose concentration &lt;45 mg/dL, with or without symptoms.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">%</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>
                                            <a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">72</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">75</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 2: Adverse Reactions in a 24-Week Trial Comparing Novolin R and Insulin Aspart in Adults with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Also Treated with NPH Insulin (adverse reactions with an incidence ≥ 5% in the Novolin R treatment group are listed)</span></p>
<table>
<col width="31%">
<col width="32%">
<col width="24%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Novolin R + NPH</span><br><span class="Bold">N= 91</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Insulin aspart + NPH</span><br><span class="Bold">N= 91</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule"></th>
<th class="Botrule Lrule Rrule"><span class="Bold">(%)</span></th>
<th class="Botrule Lrule Rrule"><span class="Bold">(%)</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was defined as an episode of blood glucose concentration &lt;45 mg/dL, with or without symptoms.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>
                                            <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">27</p></td>
</tr></tbody>
</table>
<p><span class="Italics">Children and adolescents with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span></span></p>
<p>The incidence of adverse reactions during a 24-week clinical trial comparing Novolin R and insulin aspart in children and adolescents with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus are listed in the table below.</p>
<p><span class="Bold">Table 3: Adverse Reactions in a 24-Week Trial Comparing Novolin R and Insulin Aspart in Children and Adolescents with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus Also Treated with NPH Insulin (adverse reactions with an incidence ≥5% in the Novolin R treatment group are listed)</span></p>
<table>
<col width="31%">
<col width="32%">
<col width="24%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Novolin R + NPH</span><br><span class="Bold">N= 96</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Insulin aspart + NPH</span><br><span class="Bold">N= 187</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule"></th>
<th class="Botrule Lrule Rrule"><span class="Bold">(%)</span></th>
<th class="Botrule Lrule Rrule"><span class="Bold">(%)</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> was defined as an episode of blood glucose concentration &lt;50 mg/dL, with or without symptoms.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>
                                            <a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">85</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">79</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Injection site <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> is the most commonly observed adverse reaction in patients using insulin, including Novolin R Tables 4 and 5 summarize the incidence of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in the Novolin R clinical trials. Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was defined as <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> associated with central nervous system symptoms and requiring intervention of another person or hospitalization. The rates of severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in the Novolin R clinical trials (see Section 14 for a description of the study designs) were comparable for all treatment regimens (see Tables 4 and 5).
                            <span class="Italics">[See Warnings and Precautions ( )].
                                <a href="#ID_b6491964-d031-43f0-99f6-404cf4dcebf4">5.3</a></span></p>
<p><span class="Bold">Table 4: Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in Patients with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></p>
<table>
<col width="17%">
<col width="12%">
<col width="11%">
<col width="12%">
<col width="11%">
<col width="12%">
<col width="11%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></p>
<p>Adults</p>
<p>24 weeks in combination with NPH insulin</p>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></p>
<p>Children and Adolescents</p>
<p>(age 6-18)</p>
<p>24 weeks in combination with NPH insulin</p>
</td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></p>
<p>Children</p>
<p>(age 2-6)</p>
<p>24 weeks in combination with NPH insulin</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Novolin R</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Insulin aspart</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Novolin R</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Insulin aspart</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Novolin R</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Insulin aspart</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Percent of patients (n/total N)</p></td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">19</p>
<p>(55/286)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">18</p>
<p>(105/596)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">9</p>
<p>(9/96)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">6</p>
<p>(11/187)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">12</p>
<p>(3/25)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">8</p>
<p>(2/26)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Event/patient/</p>
<p>year</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.1</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.3</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.3</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Table 5: Severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> in Patients with Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></span></p>
<table>
<col width="18%">
<col width="17%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" colspan="2" valign="top">
<p class="First">Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></p>
<p>Adults</p>
<p>24 weeks in combination with</p>
<p>NPH insulin</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Novolin R</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Insulin aspart</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Percent of patients</p>
<p>(n/total N)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">5</p>
<p>(5/91)</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">10</p>
<p>(9/91)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Event/patient/</p>
<p>year</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.3</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_0b3bd463-7493-4e9c-af40-509b2bb0a140"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">A number of medications affect glucose metabolism that may require insulin dose adjustment and particularly close monitoring for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or worsening glycemic control.</p>
<dl>
<dt>•</dt>
<dd>The following are examples of medications that may increase the blood glucose-lowering effect of insulin and increase susceptibility to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>: oral antidiabetic medications, pramlintide acetate, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics.
                                </dd>
<dt>•</dt>
<dd>The following are examples of medications that may reduce the blood glucose-lowering effect of insulin, leading to worsening of glycemic control: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives), and atypical antipsychotics.
                                </dd>
<dt>•</dt>
<dd>Beta-blockers, clonidine, and lithium salts may either potentiate or weaken the blood glucose-lowering effect of insulin.
                                </dd>
<dt>•</dt>
<dd>Alcohol can increase susceptibility to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.
                                </dd>
<dt>•</dt>
<dd>Pentamidine may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, which may sometimes be followed by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.
                                </dd>
<dt>•</dt>
<dd>The signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may be reduced or absent in patients taking sympatholytic medications such as beta-blockers, clonidine, guanethidine, and reserpine.
                                </dd>
</dl>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_464dd789-c028-4ffe-9227-89ddba42aeda"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_44fb0331-7e39-43c7-987d-08c2b8161088"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category B: All pregnancies have a background risk of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and may be decreased with good glycemic control.  It is essential for patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or a history of <span class="product-label-link" type="condition" conceptid="4024659" conceptname="Gestational diabetes mellitus">gestational diabetes</span> to maintain good glycemic control before conception and throughout pregnancy. Insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is important during pregnancy in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Therefore, women should be advised to tell their healthcare provider if they intend to become, or if they become, pregnant while taking Novolin R.</p>
<p>No reproductive toxicity studies have been performed with Novolin R.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_2aee89bc-4514-4481-83e7-ae7a9c2a74bd"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is unknown whether Novolin R is excreted in breast milk. Small amounts of human insulin are secreted into breast milk, the significance of which is not known. Use of Novolin R is compatible with breastfeeding, but insulin doses may need to be adjusted because lactation can reduce insulin requirements.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_9b03da35-9078-482d-b335-eb81f412e0f8"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of subcutaneous injections of Novolin R have been established in pediatric patients (ages 2 to18 years) with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> .  Novolin R has not been studied in pediatric patients younger than 2 years of age. Novolin R has not been studied in pediatric patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                                    <span class="Italics">[see Clinical Studies ( )]
                                        <a href="#ID_73229d7e-c47f-4e1f-955f-b5a749f9e0fa">14.3</a></span></p>
<p>In general, pediatric patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> are more susceptible to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> than adult patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. As in adults, the dosage of Novolin R must be individualized in pediatric patients based on metabolic needs and frequent monitoring of blood glucose .
                                    <span class="Italics">[see Dosage and Administration ( ) and Warnings and Precautions ( )]
                                        <a href="#ID_977d6f9c-b757-4474-91f9-9895ceb9c259">2.1</a><a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a></span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_ed66f641-93f1-41a9-88ef-ac87ffcfcebe"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In 3 controlled clinical trials 18 of 1285 patients (1.4%) with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> treated with Novolin R and insulin aspart were ≥65 years of age. In 4 controlled clinical trials 151 of 635 patients (24%) with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> were ≥65 years of age. Therefore, conclusions are limited regarding the efficacy and safety of Novolin R in patients ≥65 years of age, particularly in patients with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Pharmacokinetic/pharmacodynamic studies to assess the effect of age on Novolin R have not been performed.</p>
<p>Use caution in patients with advanced age, due to the potential for decreased renal function in this population .
                                    <span class="Italics">[see Warnings and Precautions ( and )]
                                        <a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a><a href="#ID_b0fa5b5b-1d1c-4468-a9ce-277ccb789bef">5.5</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ID_08a06ae8-44df-456d-a145-750973b5f87c"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Excess insulin administration may cause <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and, particularly when given intravenously, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.  Mild episodes of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> usually can be treated with oral glucose.  Adjustments in drug dosage, meal patterns, or exercise may be needed.  More severe episodes with <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, or neurologic impairment can be treated with intramuscular or subcutaneous glucagon or intravenous glucose.  Sustained carbohydrate intake and observation may be necessary because <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> may recur after apparent clinical recovery. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> must be corrected appropriately.  [
                            <span class="Italics">see Warnings and Precautions ( , )]
                                <a href="#ID_16c926d9-7caa-4f71-a2e1-1e72f974b05d">5.2</a><a href="#ID_b6491964-d031-43f0-99f6-404cf4dcebf4">5.3</a></span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_bee7437f-f080-4e1b-bc8c-33a30a5af579"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Novolin R (Regular Human Insulin Injection [Recombinant DNA origin] United States Pharmacopeia) is a polypeptide hormone structurally identical to native human insulin and is produced by recombinant DNA technology, utilizing (baker’s yeast) as the production organism.  Novolin R has the empirical formula C H N O S and a molecular weight of 5808.
                            <span class="Italics">Saccharomyces cerevisiae</span><span class="Sub">257</span><span class="Sub">383</span><span class="Sub">65</span><span class="Sub">77</span><span class="Sub">6</span></p>
<div class="Figure">
<a name="id-444455137"></a><img alt="Structural formula of Novolin R" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-01.jpg">
</div>
<p><span class="Bold">Figure 1:  Structural formula of Novolin R</span></p>
<p>Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection.  The pH is adjusted to 7.4.  Hydrochloric acid 2N or sodium hydroxide 2N may be added to adjust pH.  Novolin R vials are latex-free.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_5e215a76-88db-40b6-ba96-fb39f7155a62"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_6ac6eef5-3e81-495e-9ea9-28f30c3af0fc"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The primary activity of Novolin R is the regulation of glucose metabolism.  Insulins, including Novolin R, bind to insulin receptors on muscle and adipocytes and lower blood glucose by facilitating the cellular uptake of glucose and simultaneously inhibiting the output of glucose from the liver.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_65c16400-e3cd-4ffc-abc9-661a3369f281"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Novolin R is a short-acting insulin. When injected subcutaneously, the glucose-lowering effect of Novolin R begins approximately 30 minutes post-dose, is maximal between 1.5 and 3.5 hours post-dose and terminates approximately 8 hours post-dose. The onset of action of Novolin R, when administered intravenously, is more rapid in comparison to the subcutaneous administration.  When injected subcutaneously, Novolin R has a slower onset of action and longer duration of action compared to the rapid-acting insulin analogs.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_3ada60b6-c21f-4060-a4ad-4418770e4505"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">After single subcutaneous administration of 0.1 unit/kg of Novolin R to healthy subjects, peak insulin concentrations occurred between 1.5 to 2.5 hours post-dose.  On average, insulin concentrations returned to baseline at around 5 hours post-dose.</p>
<p>The effects of sex, age, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, ethnic origin, renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, pregnancy, and smoking, on the pharmacodynamics and pharmacokinetics of Novolin R have not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_dd6259f4-29d3-45df-b0a1-90892ef229c6"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_52e8f93b-c293-4191-b70e-eb3abd8d61f3"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Standard 2-year carcinogenicity studies in animals have not been performed to evaluate the carcinogenic potential of Novolin R.</p>
<p>Novolin R is not mutagenic in the following tests: The chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, the micronucleus assay in mouse polychromatic erythrocytes, and the mutation frequency assay in Chinese hamster cells.
                                    <span class="Italics">in vitro</span></p>
<p>Standard reproduction and teratology studies in animals, including fertility assessments have not been conducted with Novolin R.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_798f5522-f2e0-4019-9a6f-9f7ba9f76e1e"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">Please see for information on the pharmacokinetics and pharmacodynamics of Novolin R.
                            <span class="Bold"><span class="Italics"><a href="#ID_5e215a76-88db-40b6-ba96-fb39f7155a62">Section 12 CLINICAL PHARMACOLOGY</a></span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_682610f1-b7c9-4c7e-879e-4069226edcde"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (adults)</h2>
<p class="First">Two six‑month, open‑label, active-controlled studies were conducted to compare the safety and efficacy of Novolin R and insulin aspart in adults with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Insulin aspart was administered by subcutaneous injection immediately prior to meals and Novolin R was administered by subcutaneous injection 30 minutes before meals.  Both treatment groups also received subcutaneous injections of NPH insulin in either single or divided daily doses.  Because the two study designs and results were similar, data are shown for only one study (see Table 6)</p>
<p><span class="Bold">Table 6: Subcutaneous Novolin R Administration in Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (24 weeks; N=882)</span></p>
<table>
<col width="58%">
<col width="18%">
<col width="23%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Values are Mean ± SD</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Novolin R + NPH</span></p>
<p><span class="Bold">N=286</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Insulin aspart + NPH N=596</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline HbA1c (%)
                                                    <a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8.0 ± 1.2</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.9 ±1.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span><a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.0 ±  0.8</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-0.1 ± 0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Treatment Difference in HbA , Mean (95% confidence interval)
                                                    <span class="Sub">1c</span></p>
<p>Novolin R – insulin aspart group</p>
</td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First"> 0.2 [0.1; 0.3]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline, total insulin dose (units/kg/day)
                                                    <a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.2</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">End-of-Study, total insulin dose (units/kg/day)
                                                    <a href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.2</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.2</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-4" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-4" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">75.9 ± 13.1</p>
<p>0.9 ± 2.9</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">75.3 ± 14.5</p>
<p>0.5 ± 3.3</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1aba3d6c-1205-40cc-a270-073e698dae46"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (adults)</h2>
<p class="First">A six‑month, open‑label, active-controlled study was conducted to compare the safety and efficacy of Novolin R and insulin aspart in adults with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (Table 7). Insulin aspart was administered by subcutaneous injection immediately prior to meals and Novolin R was administered by subcutaneous injection 30 minutes before meals. Both treatment groups also received subcutaneous injections of NPH insulin in either single or divided daily doses.</p>
<p><span class="Bold">Table 7: Subcutaneous Novolin R Administration in Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (24 weeks; N=182)</span></p>
<table>
<col width="57%">
<col width="20%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Values are Mean ± SD</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Novolin R + NPH</span></p>
<p><span class="Bold">N = 91</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Insulin aspart + NPH</span></p>
<p><span class="Bold">N = 91</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">7.8 ± 1.1</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8.1 ± 1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span><a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-0.1 ± 0.8</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">-0.3 ± 1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p>
<p>Novolin R – insulin aspart group</p>
</td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">0.1 [-0.1; 0.4]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline, total insulin dose (units/kg/day)
                                                    <a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.6 ± 0.3</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.6 ± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">End-of-Study, total insulin dose (units/kg/day)
                                                    <a href="#footnote-5" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.3</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.7 ± 0.3</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-5" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-5" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">85.8 ± 14.8</p>
<p>0.4 ± 3.1</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">88.4± 13.3</p>
<p>1.2± 3.0</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_73229d7e-c47f-4e1f-955f-b5a749f9e0fa"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (children and adolescents)</h2>
<p class="First">A six‑month, open‑label, active-controlled study was conducted to compare the safety and efficacy of Novolin R and insulin aspart in children and adolescents aged 6-18 years with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (Table 8). Insulin aspart was administered by subcutaneous injection immediately prior to meals and Novolin R was administered by subcutaneous injection 30 minutes before meals. Both treatment groups also received subcutaneous injections of NPH insulin.</p>
<p><span class="Bold">Table 8:  Subcutaneous Novolin R Administration in Children and Adolescents with Type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> (24 weeks; N=283)</span></p>
<table>
<col width="57%">
<col width="20%">
<col width="22%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Values are Mean ± SD</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>The treatment difference and corresponding 95% confidence interval is based on the Analysis of Covariance Model</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Novolin R + NPH</span></p>
<p><span class="Bold">N=96</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Insulin aspart + NPH</span></p>
<p><span class="Bold">N=187</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline HbA (%)
                                                    <span class="Sub">1c</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8.3 ± 1.3</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8.3 ± 1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from Baseline HbA (%)
                                                    <span class="Sub">1c</span><a href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.1 ± 1.1</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.1 ± 1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Treatment Difference in HbA Mean (95% confidence interval)
                                                    <span class="Sub">1c,</span></p>
<p>Novolin R – insulin aspart group
                                                    <a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p>
</td>
<td class="Botrule Lrule Rrule" colspan="2" valign="top"><p class="First">0.2 [-0.1; 0.5]</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Baseline, total insulin dose (units/kg/day)
                                                    <a href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.0 ± 0.4</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.0 ± 0.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">End-of-Study, total insulin dose (units/kg/day)
                                                    <a href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.2 ± 0.4</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.2 ± 0.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">Diabetic ketoacidosis</span> n (%)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">2 (2%)</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">10 (5%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Baseline body weight (kg)
                                                    <a href="#footnote-6" class="Sup">*</a></p>
<p>Weight Change from baseline (kg)
                                                    <a href="#footnote-6" class="Sup">*</a></p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">48.7 ± 15.8</p>
<p>2.4 ± 2.6</p>
</td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">50.6 ± 19.6</p>
<p>2.7 ± 3.5</p>
</td>
</tr>
</tbody>
</table>
<p>Novolin R and insulin aspart have also been compared in an open-label, randomized, crossover trial in 26 children with type 1 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> aged 2-6 years. Patients received each treatment for 12 weeks. Insulin aspart was administered by subcutaneous injection immediately prior to meals and Novolin R was administered by subcutaneous injection 30 minutes before meals. Both treatment groups also received subcutaneous injections of NPH insulin. In this study, the mean baseline HbA was 7.8%.
                                    <span class="Sub">1c</span><br></p>
<p>The estimated HbA at end of treatment was 7.6% with Novolin R and 7.7% with insulin aspart.
                                    <span class="Sub">1c</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_dc257cfa-0738-4f03-beac-5ef409032fe5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:64725-1833-1 in a VIAL of 10 INJECTION, SOLUTIONS</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bef8e3b2-3193-4739-a06e-d9c7314e988b"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Novolin R is available in 10 mL vials (NDC 0169-1833-11 and ReliOn brand NDC 0169-1833-02).  The concentration of Novolin R is 100 USP units of human insulin (rDNA origin)/mL. One vial is provided in each sale pack.
                                    <span class="Sup">®</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55c67219-4d5b-4200-b9c2-af8fc1b4235f"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Recommended Storage</h2>
<p class="First">Unopened Novolin R vials should be stored in the refrigerator (36° - 46°F [2° - 8°C]). If carried as a spare or if refrigeration is not possible, unopened Novolin R vials can be kept at room temperature provided they are kept as cool as possible (not above 77 F [25 C]). If kept at room temperature, Novolin R vials must be discarded after 42 days even if they are unopened.
                                    <span class="Sup">o</span><span class="Sup">o</span></p>
<p>In addition, unopened Novolin R vials should be kept in their cartons so that they will stay clean and protected from light.  They should not be exposed to heat or light.
                                    <span class="Bold">Do not freeze and do not use Novolin R if it has been frozen.</span></p>
<p>An opened (In use) Novolin R vial can be kept at room temperature provided it is kept as cool as possible (not above 77 F [25 C]) and away from heat or light. Do not refrigerate after first use.
                                    <span class="Sup">o</span><span class="Sup">o</span></p>
<p>Unopened and opened (In use) Novolin R vials must be discarded 42 days after they are first kept out of the refrigerator, even if they still contain Novolin R insulin.</p>
<p><span class="Bold">Table 9: Storage Conditions for Novolin R vials</span></p>
<table>
<col width="24%">
<col width="35%">
<col width="33%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>The total time allowed at room temperature (up to 25 C) is 42 days regardless of whether the product is unopened or opened (In use)
                                                        <span class="Sup">o</span>
</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Unopened</span></p>
<p><span class="Bold">(Refrigerated)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Unopened</span></p>
<p><span class="Bold">(Room Temperature up to 77 F [25 C] )
                                                        <span class="Sup">o</span><span class="Sup">o</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold">Opened (In use)</span></p>
<p><span class="Bold">(Room Temperature up to 77 F [25 C])
                                                        <span class="Sup">o</span><span class="Sup">o</span></span></p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until expiration date</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">42 days
                                                    <a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">42 days
                                                    <a href="#footnote-8" class="Sup">*</a></p></td>
</tr>
</tbody>
</table>
<p>Infusion bags prepared as indicated under are stable at room temperature for 24 hours.  A certain amount of insulin will be initially adsorbed to the material of the infusion bag.
                                    <span class="Italics">DOSAGE AND ADMINISTRATION ( )
                                        <a href="#ID_87ef8374-86e9-47f2-918f-f404b3bde6bc">2.3</a></span></p>
<p><span class="Bold">Always remove the needle after each injection. Always use a new disposable syringe and needle for each injection to prevent contamination.</span></p>
<p>Never use insulin after the expiry date which is printed on the label and carton.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_43618bb6-caed-41a3-9b4e-27aebf06bc97"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (Patient Information and Instructions for Use)</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_e8c59fa8-054c-4697-9532-8fa7b528797b"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Instructions for All Patients</h2>
<p class="First">Maintenance of normal or near-normal glucose control is a treatment goal in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and has been associated with a reduction in some diabetic complications.  Patients should be informed about potential risks and benefits of Novolin R therapy including possible adverse reactions.  Patients should also be offered continued education and advice on insulin therapies, injection technique, life-style management, regular glucose monitoring, periodic <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> testing, recognition and management of hypo- and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, adherence to meal planning, complications of insulin therapy, timing of dose, instruction in the use of injection devices, and proper storage of insulin. Patients should be informed that frequent, patient-performed blood glucose measurements are needed to achieve optimal glycemic control and avoid both hyper- and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
<p>The patient’s ability to concentrate and react may be impaired as a result of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Patients who have frequent <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or reduced or absent warning signs of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> should be advised to use caution when driving or operating machinery.  Female patients should be advised to tell their physician if they intend to become, or if they become pregnant.</p>
<p>Patients should be instructed to always carefully check that they are administering the correct insulin to avoid medication errors between Novolin R and other insulins. Patients should check the label for the drug name Novolin R, the enlarged R letter, and the blue horizontal bar. If a prescription for Novolin R is needed, it should be written clearly to avoid <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> with other insulin products.</p>
<p><span class="Italics">Novolin is a registered trademark of Novo Nordisk A/S.
                                        <span class="Sup">®</span></span></p>
<p><span class="Italics">ReliOn is a registered trademark of Wal-Mart Stores, Inc. and is used under license by Novo Nordisk Inc.
                                        <span class="Sup">®</span></span></p>
<p>© 2002-2013 Novo Nordisk</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>ReliOn brand manufactured by:
                                    <span class="Sup">®</span></p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For Wal-Mart Stores Inc.</p>
<p>For information about Novolin R contact:</p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p><a href="#_Ref">www.novonordisk-us.com</a></p>
<p>1-800-727-6500</p>
</div>
<div class="Section" data-sectionCode="55105-1">
<a name="ID_24642107-db2e-4363-b5a2-5565cc1bba2d"></a><a name="section-15.2"></a><p></p>
</div>
<div class="Section" data-sectionCode="55106-9">
<a name="ID_ac11e819-788d-4097-9c40-c54e48b3c929"></a><a name="section-15.3"></a><p></p>
</div>
<div class="Section" data-sectionCode="51727-6">
<a name="ID_6e038657-f69b-4e5b-936d-ae5adc637d16"></a><a name="section-15.4"></a><p></p>
</div>
<div class="Section" data-sectionCode="50565-1">
<a name="ID_4d8d6e97-bf4e-4ade-9dcb-9e3ec1f920b4"></a><a name="section-15.5"></a><p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ID_ed946d28-4336-41b8-b175-e39c7617cdcd"></a><a name="section-15.6"></a><p></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f9afcfbf-3a4c-4a6c-bce2-36014b3b3cac"></a><a name="section-16"></a><p></p>
<h1>PATIENT PACKAGE INSERT</h1>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">NOVOLIN R (NO-voe-lin)
                                <span class="Sup">®</span></span></p>
<p>(Regular, Human Insulin Injection [recombinant DNA origin] USP)</p>
<p>solution for subcutaneous injection</p>
<p>Read the Patient Information leaflet that comes with Novolin R before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or your treatment. Make sure you know how to manage your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Ask your healthcare provider if you have any questions about managing your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.
                            <span class="Sup">®</span></p>
<p><span class="Bold">What is Novolin R?
                                <span class="Sup">®</span></span></p>
<p>Novolin R is a man-made insulin (recombinant DNA origin) that is used to control high blood sugar in adults and children with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.
                            <span class="Sup">®</span></p>
<p><span class="Bold">Who should not use Novolin R?
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">Do not take Novolin R if:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Your blood sugar is too low (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). After treating your low blood sugar, follow your healthcare provider’s instructions on the use of Novolin R.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>You are allergic to any of the ingredients in Novolin R. See the end of this leaflet for a complete list of ingredients in Novolin R. Check with your healthcare provider if you are not sure.
                                <span class="Sup">®</span><span class="Sup">®</span>
</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking Novolin R?
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">Before you take Novolin R, tell your healthcare providers if you:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">have liver or kidney problems.</span></dd>
<dt>•</dt>
<dd><span class="Bold">take any other medicines, especially ones commonly called TZDs (thiazolidinediones).</span></dd>
<dt>•</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, it may get worse while you take TZDs with Novolin R.
                                <span class="Bold">have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or other heart problems.</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Medical conditions can affect your insulin needs and your dose of Novolin R.
                                <span class="Bold">have any other medical conditions.</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Talk to your healthcare provider if you are pregnant or plan to become pregnant. You and your healthcare provider should talk about the best way to manage your <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> while you are pregnant.
                                <span class="Bold">are pregnant or plan to become pregnant.</span>
</dd>
<dt>•</dt>
<dd>It is not known if Novolin R passes into breast milk. You and your healthcare provider should decide if you will take Novolin R while you breast-feed.
                                <span class="Bold">are breast-feeding or plan to breast-feed.</span><span class="Sup">®</span><span class="Sup">®</span>
</dd>
</dl>
<p>including prescription and nonprescription medicines, vitamins and herbal supplements. Novolin R may affect the way
                            <span class="Bold">Tell your healthcare provider about all of the medicines you take,</span><span class="Sup">®</span></p>
<p>other medicines work, and other medicines may affect how Novolin R works.
                            <span class="Sup">®</span></p>
<p>Keep a list of your medicines with you to show all your
                            <span class="Bold">Know the medicines you take.</span></p>
<p>healthcare providers and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take Novolin R?
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Novolin R comes in 10 mL vials for use with a syringe.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Take Novolin R exactly as prescribed.
                                    <span class="Sup">®</span></span></dd>
<dt>•</dt>
<dd>Your healthcare provider will tell you how much Novolin R to take and when to take it.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Do not make any changes to your dose or type of insulin unless you are told to do so by your healthcare provider.
                                </dd>
<dt>•</dt>
<dd>The effects of Novolin R usually start working within about 30 minutes after your injection and usually lasts for up to 8 hours.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>your total dose of insulin, your dose of Novolin R, your dose of longer-acting insulin, or the number of injections of insulin you use.
                                <span class="Bold">While using Novolin R your healthcare provider may change
                                    <span class="Sup">®</span></span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>with any insulins other than NPH in the same syringe.
                                <span class="Bold">Do not mix Novolin R
                                    <span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>Novolin R may affect your blood sugar levels faster if you inject it into the skin of your abdomen (stomach area).
                                <span class="Bold">Inject Novolin R under your skin (subcutaneously) of your abdomen (stomach area), upper arms, buttocks or upper legs.
                                    <span class="Sup">®</span></span><span class="Bold"><span class="Sup">®</span></span><span class="Bold">Never inject Novolin R into a vein or into a muscle.
                                    <span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd><span class="Bold">Do not use Novolin R in an insulin pump.
                                    <span class="Sup">®</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">Change (rotate) your injection site within the chosen area (for example, stomach or upper arm) with each dose. Do not inject into the same spot for each injection.</span></dd>
<dt>•</dt>
<dd>Talk to your healthcare provider if you have any questions.  Your healthcare provider should show you how to inject Novolin R before you start taking it.
                                <span class="Bold">Read the instructions for use that comes with your Novolin R.
                                    <span class="Sup">®</span></span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>You can treat mild low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) by drinking or eating something sugary right away (fruit juice, sugar candies, or glucose tablets). It is important to treat low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) right away because it could get worse and could lead to passing out (<span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
                                <span class="Bold">If you take too much Novolin R, your blood sugar may <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> too low (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).
                                    <span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>If high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>) is not treated it can lead to serious problems, like <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (passing out), <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Follow your healthcare provider’s instructions for treating high blood sugar. Know your symptoms of high blood sugar which may include:
                                <span class="Bold">If you forget to take your dose of Novolin R, your blood sugar may go too high (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>).
                                    <span class="Sup">®</span></span><dl>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">increased thirst</span>
                                        </dd>
<dt>∘</dt>
<dd>frequent urination and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>
                                        </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>
                                        </dd>
<dt>∘</dt>
<dd>loss of appetite
                                        </dd>
<dt>∘</dt>
<dd>fruity smell on breath
                                        </dd>
<dt>∘</dt>
<dd>high amounts of sugar and <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your urine
                                        </dd>
<dt>∘</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (throwing up) or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>
                                        </dd>
<dt>∘</dt>
<dd>a hard time breathing
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd>Do not share needles or syringes with others. You may give an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to them or get an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> from them.
                                </dd>
<dt>•</dt>
<dd>Ask your healthcare provider what your blood sugars should be and how often you should check your blood sugar levels for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (too low blood sugar) and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> (too high blood sugar).
                                <span class="Bold">Check your blood sugar levels.</span>
</dd>
</dl>
<p><span class="Bold">Your insulin dosage may need to change because of:</span></p>
<dl>
<dt>•</dt>
<dd>illness
                                </dd>
<dt>•</dt>
<dd>stress
                                </dd>
<dt>•</dt>
<dd>other medicines you take
                                </dd>
<dt>•</dt>
<dd>change in diet
                                </dd>
<dt>•</dt>
<dd>change in physical activity or exercise
                                </dd>
<dt>•</dt>
<dd>surgery
                                </dd>
</dl>
<p>See the end of this patient information for instructions about preparing and giving the injection.</p>
<p><span class="Bold">What should I avoid while taking Novolin R?
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Alcohol may affect your blood sugar when you take Novolin R. This could lead to blood sugar that is too low (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).
                                <span class="Bold">Drinking alcohol.</span><span class="Bold"><span class="Sup">®</span></span><dl>
<dt>∘</dt>
<dd>You may have trouble paying attention or reacting if you have low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). Be careful when you drive a car or operate machinery. Ask your healthcare provider if it is alright for you to drive if you often have:
                                        <span class="Bold">Driving and operating machinery.</span>
</dd>
<dt>∘</dt>
<dd>low blood sugar
                                        </dd>
<dt>∘</dt>
<dd>decreased or no warning signs of low blood sugar
                                        </dd>
</dl>
</dd>
</dl>
<p><span class="Bold">What are the possible side effects of Novolin R?
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">Novolin R may cause serious side effects, including:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">Low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>).</span></dd>
</dl>
<p>The general symptoms of low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) may be one or more of the following:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span>
                                </dd>
<dt>•</dt>
<dd>fast heart beat
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your hands, feet, lips or tongue
                                </dd>
<dt>•</dt>
<dd>trouble concentrating or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>
                                </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
                                </dd>
</dl>
<p>Very low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>) can cause <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> (passing out), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, temporary or permanent brain problems or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Talk to your healthcare provider about how to tell if you have low blood sugar and what to do if this happens while taking Novolin R. Know your symptoms of low blood sugar. Follow your healthcare provider’s instructions for treating low blood sugar.
                            <span class="Bold"><span class="Sup">®</span></span></p>
<p>Talk to your healthcare provider if low blood sugar is a problem for you. Your dose of Novolin R may need to be changed.
                            <span class="Bold"><span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>A decrease of potassium in your blood can cause breathing problems, a change in your heartbeat and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
                                <span class="Bold">Low <span class="product-label-link" type="condition" conceptid="4107462" conceptname="k">blood potassium</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>).</span>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> (whole body reaction). You can have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> that may be life-threatening. Get medical help right away if you have any of these symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>:</span><dl>
<dt>•</dt>
<dd>a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> over your body
                                        </dd>
<dt>•</dt>
<dd>have trouble breathing
                                        </dd>
<dt>•</dt>
<dd>a fast heartbeat
                                        </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>
                                        </dd>
<dt>•</dt>
<dd>feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your hands and feet.</span></dd>
<dt>•</dt>
<dd>Taking certain <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> pills called thiazolidinediones or “TZDs? with Novolin R may cause <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in some people.  This can happen even if you have never had <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or heart problems before.  If you already have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> it may get worse while you take TZDs with Novolin R .  Your healthcare provider should monitor you closely while you are taking TZDs with Novolin R.  Tell your healthcare provider if you have any new or worse symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> including:
                                <span class="Bold"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>.</span><span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>
                                        </dd>
</dl>
</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your ankles or feet
                                </dd>
<dt>•</dt>
<dd>sudden <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>
                                </dd>
<dt> </dt>
<dd>Treatment with TZDs and Novolin R may need to be adjusted or stopped by your healthcare provider if you have new or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.
                                <span class="Sup">®</span>
</dd>
</dl>
<p><span class="Bold">Other side effects of Novolin R may include:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>You may get <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> at the injection site. If you keep having <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, or they are serious, talk to your healthcare provider. You may need to stop using Novolin R and use a different insulin. Do not inject insulin into skin that is red, swollen, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span>.
                                <span class="Bold">Reactions at the injection site (local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>).</span><span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>The fatty tissue under the skin may shrink (<span class="product-label-link" type="condition" conceptid="4087489" conceptname="Lipoatrophy">lipoatrophy</span>) or thicken (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">lipohypertrophy</span>) at the injection site. Change (rotate) the site where you inject your insulin to help reduce the chance of developing these skin changes. Do not inject insulin into this type of skin.
                                <span class="Bold">Changes at the injection site (<span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span>).</span>
</dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span>.</span></dd>
<dt>•</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">Swelling</span> of your arms and legs.</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects from Novolin R. Ask your healthcare provider or pharmacist for more information.
                            <span class="Sup">®</span></p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store Novolin R?
                                <span class="Sup">®</span></span></p>
<p><span class="Bold">Unopened Novolin R:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Unopened vials can be used until the expiration date on the Novolin R label, if the medicine has been stored in a refrigerator.
                                <span class="Bold">Unopened Novolin R should be kept in the refrigerator between 36°F to 46°F (2° to 8°C).
                                    <span class="Sup">®</span></span><span class="Bold"><span class="Sup">®</span></span>
</dd>
<dt>•</dt>
<dd>If refrigeration is not possible or if you want to carry a spare Novolin R vial you can keep the unopened vial at room temperature for up to 42 days, as long as it is kept at or below 77°F (25°C). Throw away the vial 42 days after it is first kept out of the refrigerator, even if the vial is unopened.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Do not freeze. Do not use Novolin R if it has been frozen.
                                <span class="Sup">®</span>
</dd>
<dt>•</dt>
<dd>Keep unopened Novolin R in the carton to protect it from light.
                                <span class="Sup">®</span>
</dd>
</dl>
<p><span class="Bold">Novolin R in use:
                                <span class="Sup">®</span></span></p>
<dl>
<dt>•</dt>
<dd>Keep at room temperature below 77°F (25°C).
                                </dd>
<dt>•</dt>
<dd>Keep vials away from heat or light.
                                </dd>
<dt>•</dt>
<dd>Do not refrigerate an opened vial.
                                </dd>
<dt>•</dt>
<dd>Throw away the vial 42 days after it is first kept out of the refrigerator, even if there is insulin left in the vial.
                                </dd>
</dl>
<p><span class="Bold">Never use insulin after the expiration date which is printed on the label and carton.</span></p>
<p><span class="Bold">General information about Novolin R
                                <span class="Sup">®</span></span></p>
<p>Medicines are sometimes prescribed for conditions that are not mentioned in the patient leaflet. Do not use Novolin R for a condition for which it was not prescribed. Do not give Novolin R to other people, even if they have the same symptoms you have. It may harm them.
                            <span class="Sup">®</span><span class="Sup">®</span></p>
<p>This leaflet summarizes the most important information about Novolin R. If you would like more information about Novolin R or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about Novolin R that is written for healthcare professionals.
                            <span class="Sup">®</span><span class="Sup">®</span><span class="Sup">®</span></p>
<p>For more information about Novolin R, call 1-800-727-6500 or go to .
                            <span class="Sup">®</span><a href="#_Ref">www.novonordisk-us.com</a></p>
<p><span class="Bold">What are the ingredients in Novolin R?
                                <span class="Sup">®</span></span></p>
<p>Regular Human Insulin Injection (recombinant DNA origin) USP.
                            <span class="Bold">Active ingredient:</span></p>
<p>glycerol, metacresol, zinc chloride, water for injection, hydrochloric acid and sodium hydroxide may be added.
                            <span class="Bold">Inactive ingredients:</span></p>
<p>All Novolin R vials are latex-free.
                            <span class="Sup">®</span></p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p>Date of issue: 03/2013</p>
<p><span class="Italics">Novolin is a registered trademark of Novo Nordisk A/S.
                                <span class="Sup">®</span></span></p>
<p>© 2002-2013 Novo Nordisk</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For information about Novolin R contact:
                            <span class="Sup">®</span></p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p>1-800-727-6500</p>
<p>www.novonordisk-us.com</p>
<p><span class="Bold">Patient Instructions for Use</span></p>
<p><span class="Bold">Novolin R 10 mL vial (100 Units/mL, U-100)
                                <span class="Sup">®</span></span></p>
<p>Please read the following Instructions for Use carefully before using your Novolin R 10 mL vial and
                            <span class="Sup">®</span></p>
<p>each time you get a refill. You should read the instructions in this manual even if you have used an</p>
<p>insulin 10 mL vial before. There may be new information.</p>
<p>Before starting, gather all of the supplies that you will need to use for preparing and giving your insulin</p>
<p>injection.</p>
<p>Never re-use syringes and needles.</p>
<p><span class="Bold">How should I use the Novolin R vial?</span></p>
<p>1. Check to make sure that you have the correct type of insulin.  This is especially important if you use different types of insulin.</p>
<p>2. Look at the vial and the insulin.  The insulin should be clear and colorless.  The tamper-resistant cap should be in place before the first use.  If the cap had been removed before your first use of the vial, or if the insulin is cloudy, colored, or contains any particles, do not use it and call Novo Nordisk at 1-800-727-6500.</p>
<p>3. Wash your hands with soap and water.  Clean your injection site with an alcohol swab and let the injection site dry before you inject.  Talk with your healthcare provider about how to rotate injection sites and how to give an injection.</p>
<p>4. If you are using a new vial, pull off the tamper-resistant cap.</p>
<div class="Figure">
<a name="id1558"></a><img alt="Pull off tamper resistant cap" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-02.jpg">
</div>
<p>Wipe the rubber stopper with an alcohol swab.</p>
<div class="Figure">
<a name="id1560"></a><img alt="Wipe the rubber stopper with an alcohol swab" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-03.jpg">
</div>
<p>5. Do not roll or shake the vial.  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Shaking</span> right before the dose is drawn into the syringe may cause bubbles or foam. This can cause you to draw up the wrong dose of insulin.</p>
<p>6. Pull back the plunger on the syringe until the black tip reaches the marking for the number of units you will inject.</p>
<div class="Figure">
<a name="id1563"></a><img alt="Pull back the plunger" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-04.jpg">
</div>
<p>7. Push the needle through the rubber stopper of the vial.</p>
<div class="Figure">
<a name="id1565"></a><img alt="Push the needle through the rubber stopper of the vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-05.jpg">
</div>
<p>8. Push the plunger all the way in to force air into the vial.</p>
<div class="Figure">
<a name="id1567"></a><img alt="Push the plunger all the way in" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-06.jpg">
</div>
<p>9. Turn the vial and syringe upside down and slowly pull the plunger back to a few units beyond the correct dose.</p>
<div class="Figure">
<a name="id1569"></a><img alt="Turn the vial and syringe up and down" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-07.jpg">
</div>
<p>10. If there are any air bubbles, tap the syringe gently with your finger to raise the air bubbles to the top.  Then slowly push the plunger to the marking for your correct dose.  This process should move any air bubbles present in the syringe back into the vial.</p>
<div class="Figure">
<a name="id1571"></a><img alt="Tap the syringe gently" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-08.jpg">
</div>
<p>11. Check to make sure you have the right dose of Novolin R in the syringe.</p>
<p>12. Pull the syringe out of the vial’s rubber stopper.</p>
<p>13. Your healthcare provider should tell you if you need to pinch the skin before and while inserting the needle.  This can vary from patient to patient so it is important to ask your healthcare provider if you did not receive instructions on pinching the skin. Insert the needle into the skin.  Press the plunger of the syringe to inject the insulin. When you are finished injecting the insulin, pull the needle out of your skin. You may see a drop of Novolin R at the needle tip.  This is normal and has no effect on the dose you just received.  If you see blood after you take the needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol wipe.
                            <span class="Bold">Do not rub the area.</span></p>
<div class="Figure">
<a name="id1576"></a><img alt="Press the plunger of the syringe to inject the insulin" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=6ede8238-f902-478d-8cee-997855045083-09.jpg">
</div>
<p>14. After your injection, do not recap the needle. Place used syringes, needles and used insulin vials in a disposable puncture-resistant sharps container, or some type of hard plastic or metal container with a screw on cap such as a detergent bottle or coffee can.</p>
<p>15. Ask your healthcare provider about the right way to throw away used syringes and needles.  There may be state or local laws about the right way to throw away used syringes and needles. Do not throw away used needles and syringes in household trash or recycle.</p>
<p><span class="Bold">How should I mix Novolin R with NPH insulin?</span></p>
<p>Different insulins should be mixed only under instruction from a healthcare provider.
                            <span class="Bold">Do not mix</span></p>
<p>Novolin R should be mixed with NPH insulin right before use.  When you are mixing Novolin R insulin with NPH insulin, always
                            <span class="Bold">Novolin R with any other type of insulin except NPH insulin.</span><span class="Bold">draw the Novolin R (clear) insulin into the syringe first.</span></p>
<p>1. Add together the total number of units of NPH and Novolin R that you need to inject.  Your total dose of medicine to inject will be the amount of NPH and Novolin R in the syringe after drawing up both insulins. For example, if you need 5 units of NPH and 2 units of Novolin R, the total dose of insulin in</p>
<p>the syringe would be 7 units.</p>
<p><span class="Bold">Preparing your NPH and Novolin R insulins for injection:</span></p>
<p>2. Roll the NPH vial between your hands until all of the liquid in the vial is cloudy.</p>
<p>3. Pull the plunger of the syringe down so that the dark end is lined up to the number of units needed for your NPH insulin.  This will draw into the syringe the same amount of air as the NPH dose needed.</p>
<p>4. Put the needle through the rubber stopper of the cloudy NPH insulin bottle. After you inject the air into the NPH vial, remove the needle from the vial but do not withdraw any of the NPH insulin.  Putting air in the bottle makes it easier to draw the insulin out of the bottle.</p>
<p>5. Pull the plunger of the syringe down to the number of units needed for your Novolin R insulin.  After you draw the air into the syringe, inject the air into the Novolin R vial.</p>
<p><span class="Bold">Drawing up and mixing your NPH and Novolin R insulins for injection:</span></p>
<p>6. With the needle in place, turn the clear insulin vial of Novolin R upside down and slowly pull the plunger back to a few units beyond the right dose of Novolin R. The tip of the needle must be in the Novolin R liquid to get the full dose and not an air dose.</p>
<p>7. Check the syringe for air bubbles. If you see air bubbles, tap the syringe gently with your finger to</p>
<p>raise the air bubbles to the top.  Then slowly push the plunger to the marking for your correct dose. This process should move any air bubbles in the syringe back into the vial.</p>
<p>8. After withdrawing the needle from the Novolin R vial, insert the needle into the NPH vial.</p>
<p>9. Turn the NPH vial upside down with the syringe and needle still in the vial. Slowly pull the plunger back to withdraw your NPH dose.</p>
<p><span class="Bold">Remember the total dose of medicine in the syringe should be your total dose of NPH and Novolin R insulins. (See Step 1 under “How should I mix Novolin R with NPH insulin??)</span></p>
<p>10.  Inject your insulin right away otherwise it might not work properly.</p>
<p>This Patient Instructions for Use has been approved by the Food and Drug Administration.</p>
<p>Date of Issue:  03/2013</p>
<p>Novolin is a registered trademark of Novo Nordisk A/S.
                            <span class="Sup">®</span></p>
<p>© 2002-2013 Novo Nordisk</p>
<p>Manufactured by:</p>
<p>Novo Nordisk A/S</p>
<p>DK-2880 Bagsvaerd, Denmark</p>
<p>For information about Novolin R contact:</p>
<p>Novo Nordisk Inc.</p>
<p>800 Scudders Mill Road</p>
<p>Plainsboro, New Jersey 08536</p>
<p>1-800-727-6500</p>
<p><a href="http://www.novonordisk-us.com">www.novonordisk-us.com</a></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>NOVOLIN R (HUMAN INSULIN) INJECTION, SOLUTION</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78dadbee-c3b6-4d62-a338-731b24cc7ef0&amp;name=64725-1833.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NOVOLIN
                                     		
					R</strong><br><span class="contentTableReg">human insulin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN OTC DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64725-1833(NDC:0169-1833)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>INSULIN HUMAN</strong> (INSULIN HUMAN) </td>
<td class="formItem">INSULIN HUMAN</td>
<td class="formItem">100 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ZINC CHLORIDE</strong></td>
<td class="formItem">7 ug  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">16 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METACRESOL</strong></td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64725-1833-1</td>
<td class="formItem">10 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019938</td>
<td class="formItem">06/25/1991</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>TYA Pharmaceuticals
							(938389038)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>TYA Pharmaceuticals (938389038)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">TYA Pharmaceuticals</td>
<td class="formItem"></td>
<td class="formItem">938389038</td>
<td class="formItem">RELABEL(64725-1833), REPACK(64725-1833)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a2c745d7-1b63-4064-b6a1-e18e43b318ad</div>
<div>Set id: 78dadbee-c3b6-4d62-a338-731b24cc7ef0</div>
<div>Version: 2</div>
<div>Effective Time: 20130309</div>
</div>
</div> <div class="DistributorName">TYA Pharmaceuticals</div></p>
</body></html>
